UCB's Cimzia(R) Approved In The U.S. For Adult Patients Suffering From Moderate To Severe Rheumatoid Arthritis (Medical News Today)
Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that the U.S. Food and Drug Administration (FDA) has approved Cimzia , for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). Cimzia (certolizumab pegol), is a PEGylated anti-TNFa (Tumor Necrosis Factor alpha). The product is currently being developed by UCB.

Stem Cell Therapeutics Corp. Announces The FDA Has Lifted Its Clinical Hold On The Phase IIb Stroke Trial (Medical News Today)
Stem Cell Therapeutics Corp. ("SCT" or "the Company") (TSX VENTURE:SSS) is pleased to announce the U.S. Food and Drug Administration ("FDA") has provided a verbal confirmation to remove its clinical hold placed on NTx -265 on September 18, 2008.

FDA grants approval for use of RISPERDAL CONSTA as both a monotherapy and adjunctive therapy in the maintenance ... (EurekAlert!)
( Golin/Harris International ) Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. today announced the US Food and Drug Administration has approved the Supplemental New Drug Applications for the use of RISPERDAL CONSTA (risperidone) Long-Acting Treatment as both monotherapy and adjunctive therapy to lithium or valproate in the maintenance treatment of bipolar I disorder. Bipolar I ...